Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases. Co.'s portfolio includes soluble guanylate cyclase (sGC) stimulators that modulate a key node in a fundamental signaling network in both the central nervous system (CNS) and the periphery. The nitric oxide (NO) sGC cyclic guanosine monophosphate (cGMP) signaling pathway is a fundamental mechanism that controls key aspects of physiology throughout the body. The NO-sGC-cGMP pathway regulates biological functions including mitochondrial function, neuronal function, inflammation, and hemodynamics. The CYCN stock yearly return is shown above.
The yearly return on the CYCN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CYCN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|